Clinical Trial Update: A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD [Phase 3]

View source ↗

Summary

A Phase 3 trial completed comparing the lung function effects of the COPD treatment BGF when formulated with an HFA propellant versus a next-generation propella…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BGF with HFA Propellant
• BGF with Next-Generation Propellant

Snippet

Sponsor: AstraZeneca | Conditions: COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Status: COMPLETED